Changes in VEGF and VEGFR immunohistochemical staining, together with decreases of the CD31-positive intratumoral vascular network, corroborate the powerful antiangiogenic and antiproliferative effect of sorafenib on thyroid tumor cells. Here, PECAM1 is linked to thyroid tumor.